Affinity Asset Advisors LLC Invests $3.84 Million in HilleVax, Inc. (NASDAQ:HLVX)

Affinity Asset Advisors LLC bought a new stake in HilleVax, Inc. (NASDAQ:HLVX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 265,859 shares of the company’s stock, valued at approximately $3,844,000. Affinity Asset Advisors LLC owned about 0.53% of HilleVax at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Catalys Pacific LLC acquired a new position in shares of HilleVax in the 4th quarter valued at about $21,009,000. Ensign Peak Advisors Inc raised its holdings in HilleVax by 164.8% in the second quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company’s stock valued at $4,508,000 after buying an additional 194,038 shares during the period. Dimensional Fund Advisors LP lifted its position in HilleVax by 31.7% during the second quarter. Dimensional Fund Advisors LP now owns 152,602 shares of the company’s stock valued at $2,204,000 after buying an additional 36,690 shares in the last quarter. Fred Alger Management LLC grew its stake in HilleVax by 9.7% during the second quarter. Fred Alger Management LLC now owns 136,166 shares of the company’s stock worth $1,969,000 after buying an additional 12,044 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of HilleVax by 35.1% in the second quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company’s stock worth $1,357,000 after acquiring an additional 24,410 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of HilleVax stock opened at $1.80 on Wednesday. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The business’s 50 day simple moving average is $1.80 and its 200-day simple moving average is $9.29.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). Research analysts anticipate that HilleVax, Inc. will post -2.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HLVX. Stifel Nicolaus lowered shares of HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the company from $34.00 to $3.00 in a report on Tuesday, July 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $5.00 target price (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Leerink Partners downgraded HilleVax from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. HC Wainwright restated a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a report on Monday, August 12th. Finally, Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Six investment analysts have rated the stock with a hold rating, According to MarketBeat.com, HilleVax has a consensus rating of “Hold” and a consensus price target of $9.20.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.